By The pharmaceutical company Roche has announced that two phase III trials of the potential Alzheimer’s drug gantenerumab did not achieve the goal of slowing clinical decline in participants with early Alzheimer’s disease.
Alzheimer’s drug gantenerumab fails to slow decline in phase III clinical trial
Close Up Scientist using microscope in laboratory room while making medical testing and research
Comments